<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03079115</url>
  </required_header>
  <id_info>
    <org_study_id>121-2016006</org_study_id>
    <nct_id>NCT03079115</nct_id>
  </id_info>
  <brief_title>High Dose Atorvastatin for Preventing Periprocedural Ischemic Brain Damage During Carotid Artery Stenting</brief_title>
  <acronym>PICAS</acronym>
  <official_title>Efficacy of Two Different Doses of Atorvastatin for Prevention of Periprocedural Ischemic Brain Damage in Chinese Patients Undergoing Carotid Artery Stenting (CAS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to test whether a short-term, high-dose atorvastatin treatment (80mg once a
      daily (QD) from 3 days before to 3 days after CAS, then 20 mg QD until 30 days after CAS) is
      superior to conventional-dose atorvastatin treatment (20 mg QD from 3 days before to 30 days
      after CAS), in terms of efficacy for prevention of periprocedural ischemic brain damage in
      Chinese patients undergoing CAS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chinese patients with carotid stenosis scheduled for selective CAS will be randomized into
      two groups. The High-dose Atorvastatin group will receive Atorvastatin 80 mg QD from 3 days
      before to 3 days after CAS, then 20 mg QD until 30 days after CAS, while the
      Conventional-dose Atorvastatin group will receive Atorvastatin 20 mg QD from 3 days before to
      30 days after CAS. All patients will receive cerebral diffusion-weighted (DW)-MRI within 7
      days before CAS. Then, they will also receive repeated DW-MRI within 5 days after CAS.
      Efficacy for prevention of periprocedural ischemic brain damage of the two different
      Atorvastatin treatments will be compared, in terms of periprocedural incidence of transient
      ischemic attack (TIA)/ ischaemic stroke or new ischemic lesions on cerebral DW-MRI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>brain damage</measure>
    <time_frame>30 days</time_frame>
    <description>composite incidence of new ischemic lesion on post-CAS cerebral DW-MRI, TIA or ischaemic stroke within 30 days after CAS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ischemic brain damage-1</measure>
    <time_frame>within 5 days</time_frame>
    <description>incidence of new ischemic lesion on post-CAS DW-MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ischemic brain damage-2</measure>
    <time_frame>within 5 days</time_frame>
    <description>number of new lesions on post-CAS DW-MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ischemic brain damage-3</measure>
    <time_frame>within 5 days</time_frame>
    <description>incidence of new lesion &gt; 5 mm on post-CAS DW-MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ischemic brain damage-4</measure>
    <time_frame>30 days</time_frame>
    <description>composite incidence of TIA or ischaemic stroke within 30 days after CAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death, any stroke, or myocardial infarction</measure>
    <time_frame>30 days</time_frame>
    <description>composite incidence of death, any stroke, or myocardial infarction within 30 days after CAS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Carotid Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>High-dose Atorvastatin Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose Atorvastatin (80 mg QD from 3 days before to 3 days after carotid artery stenting, thereafter conventional dose of Atorvastatin with 20mg QD until 30 days after CAS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional-dose Atorvastatin Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Conventional dose Atorvastatin (20mg QD from 3 days before to 30 days after CAS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose Atorvastatin</intervention_name>
    <description>high-dose Atorvastatin (80 mg QD from 3 days before to 3 days after CAS, and thereafter 20mg QD until 30 days after CAS)</description>
    <arm_group_label>High-dose Atorvastatin Arm</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional-dose Atorvastatin</intervention_name>
    <description>conventional-dose Atorvastatin(20 mg QD from 3 days before to 30 days after CAS).</description>
    <arm_group_label>Conventional-dose Atorvastatin Arm</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 50% stenosis of internal carotid artery in symptomatic patients; or ≥ 70% stenosis
             of internal carotid artery in asymptomatic patients

          -  received statin therapy for ≥ 2weeks before inclusion

        Exclusion Criteria:

          -  nonatherosclerotic carotid disease (dissection, radiation-induced stenosis)

          -  received endovascular procedure within 30 days before inclusion

          -  CAS during the procedure of urgent endovascular therapy for acute ischaemic stroke

          -  need for oral anticoagulant therapy

          -  high risk of bleeding or contraindications to antiplatelet therapy (eg: platelet count
             &lt;70 X 109/L)

          -  active hepatic disease or hepatic dysfunction, or aspartate aminotransferase (AST) or
             alanine aminotransferase (ALT) &gt; 1.5 upper normal limit

          -  myopathy or increased creatine kinase (CK) &gt; 2 upper normal limit

          -  renal failure with serum creatinine (Scr) &gt; 3 mg/dl or 264μmol/L

          -  unable to undergo MRI because of claustrophobia or pacemaker

          -  pregnancy, lactation, or child bearing potential women without any effective
             contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Lu, M.D.</last_name>
    <phone>+86 10 85136282</phone>
    <email>frente.lu@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xin Wang</last_name>
    <phone>+86 10 58115037</phone>
    <email>wangxinannie@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Wang</last_name>
      <phone>+8613661174001</phone>
      <email>wangxinannie@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2017</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Hospital</investigator_affiliation>
    <investigator_full_name>Jun Lu</investigator_full_name>
    <investigator_title>Attending Physician; MD</investigator_title>
  </responsible_party>
  <keyword>Atorvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Stenosis</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

